Mechanisms of anaemia in patients with malignancy: Implications for the clinical use of recombinant human erythropoietin

Medical Oncology

Volumn 17, Issue SUPPL. 1, 2000, Pages

  Cazzola, M ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Anaemia; Erythropoiesis; Haematological malignancies; Recombinant human erythropoietin (rHuEPO)

Indexed keywords

CISPLATIN; CYTOKINE; ERYTHROPOIETIN; INTERLEUKIN 1; RECOMBINANT ERYTHROPOIETIN; TUMOR NECROSIS FACTOR;

ANEMIA; CANCER; CANCER CHEMOTHERAPY; CONFERENCE PAPER; CYTOKINE RELEASE; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED DISEASE; HEMATOCRIT; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT INDICATION; TREATMENT OUTCOME;

ANEMIA; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; ERYTHROPOIESIS; ERYTHROPOIETIN, RECOMBINANT; HUMANS; LEUKEMIA; LYMPHOMA; PROGNOSIS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 0034528683     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (42)

1. Role of the kidney in erythropoiesis
2. Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidneys
3. Localization of erythropoietin synthetizing cells in murine kidneys by in situ hybridization
4. Quantitation of erythropoietin-producing cells in kidneys of mice by in situ hybridisation. Correlation with hematocrit, renal eryhropoietin mRNA, and serum erythropoietin concentration
5. Serum immunoreactive erythropoietin in patients with idiopathic aplastic and Faconi's anaemia
6. Serum erythropoietin levels in patients receiving intensive chemotherapy and radiotherapy
7. Marked erythropoietin increase before fall in Hb after treatment with cytostatic drugs suggests mechanism other than anaemia for stimulation
8. Serum erythropoietin levels during haematinic therapy
9. New tools for clinical evaluation of erythropoiesis and iron status in man
10. Red blood cell precursor mass as an independent determinant of serum erythropoietin level
11. Erythropoietin receptor. Subunit structure and activation
12. Quantitation of specific binding of erythropoietin to human erythroid colony-forming cells
13. Purification of human blood burst-forming units-erythroid and demonstration of the evolution of erythropoietin receptors
14. Erythropoietin receptor characteristics on primary human erythroid cells
15. Use of recombinant human erythropoietin outside the setting of uremia
16. Erythropoietin retards DNA breakdown and prevents programmed cell death in erythroid progenitor cells
17. Erythropoietin is both a mitogen and a survival factor
18. Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through bcl-XL and bcl-2
19. Control of red cell production: The role of programmed cell death (apoptosis) and erythropoietin
20. Cancer-related anemia. Its causes and characteristics
21. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production
22. Monokines inhibiting erythropoietin production in human hepatoma cultures and in isolated perfused rat kidneys
23. Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis
24. Progress in understanding the pathogenesis of the anemia or chronic disease
25. Decreased erythropoietin response in patients with the anemia of cancer
26. Preliminary clinical experience with cis-diamminedichloroplatinum (II) (NSC 119875, CACP)
27. Toxic effects of cisdichrolodiammine-platinum (II) in man
28. Serum immunoerythropoietin levels in patients with cancer receiving cisplatin-based chemotherapy
29. Cisplatin-associated anemia: An erythropoietin deficiency syndrome
30. Anemia in children with cancer is associated with decreased erythropoietin activity and not with inadequate erythropoietin production
31. Quantitative assessment of erythropoiesis in haemodialysis patients demonstrates gradual expansion of erythroblasts during constant treatment with recombinant human erythropoietin
32. Pharmacokinetics and effects of recombinant human erythropoiefin after intravenous and subcutaneous injection in healthy volunteers
33. The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects
34. Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I/II clinical trial
35. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin lymphoma. Dose finding and identification of predictors of response
36. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial
37. Perspectives in iron metabolism
38. Adequacy of iron supply for erythropoiesis: In vivo observations in humans
39. Recombinant human erythropoietin treatment in cisplatin-associated anaemia: A randomised, double-blind trial with placebo
40. Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer
41. Prevention of chemotherapy-induced anaemia by the use of erythropoietin in patients with primary malignant bone tumours (a double-blind, randomised, phase III study)
42. Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer